EpicentRx, Inc, San Diego, CA, USA.
Clinical Trials Innovations, Mountain View, CA, USA.
Cancer Metastasis Rev. 2024 Dec;43(4):1573-1578. doi: 10.1007/s10555-024-10207-5. Epub 2024 Aug 23.
The expression "lost at sea" means to be confused or perplexed. By extension, lost at SCLC references the current confusion about how to circumvent the chemoresistance, particularly platinum resistance, which so plagues the treatment of extensive-stage small cell lung cancer (ES-SCLC) that in 2012 the US National Cancer Institute (NCI) designated it a "recalcitrant cancer." Over a decade later, despite the approval of immune checkpoint inhibitors and the conditional approval of lurbinectedin, the prognosis for ES-SCLC, and especially platinum-resistant ES-SCLC, has scarcely improved. The focus of this review, which briefly summarizes current treatment options for ES-SCLC, is on five clinical-stage therapies with the potential to successfully reverse the platinum resistance that is perhaps the biggest obstacle to better clinical outcomes.
“迷失在大海中”的意思是感到困惑或困惑。引申开来，SCLC 迷失是指目前对于如何规避化疗耐药，特别是铂耐药，的困惑，这种耐药性严重困扰着广泛期小细胞肺癌（ES-SCLC）的治疗，以至于 2012 年美国国家癌症研究所（NCI）将其指定为“难治性癌症”。十多年后，尽管免疫检查点抑制剂获得批准，仑比替尼有条件批准，ES-SCLC 的预后，特别是铂耐药的 ES-SCLC，几乎没有改善。本文简要总结了 ES-SCLC 的当前治疗选择，重点介绍了五种具有潜在能力的临床阶段治疗方法，以成功逆转铂耐药，这可能是改善临床结果的最大障碍。
